Abbvie Return on Equity

Abbvie (ABBV) currently reports a ROE of 13.23%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Abbvie's ROE history and peer comparisons.

Abbvie's ROE of 13.23% is lower than the Healthcare sector average of 29.39%. That is roughly 55.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Abbvie's current 13.23% should be judged against Healthcare norms (sector average: 29.39%) and against ABBV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 13.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Abbvie, and consider following ABBV for alerts when major investors trade the stock.

Abbvie is classified in the Healthcare sector. On ROE, it currently shows 13.23% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABBV with unrelated industries.